Key insights
- Ideaya Biosciences plans to initiate registrational trials for its DLL3-targeting antibody drug conjugate, IDE849, in neuroendocrine carcinomas and small cell lung cancer by year-end. The company will launch a single-arm extension cohort in its Phase 1/2 trial to support potential accelerated approval, with plans for a Phase 3 trial to support full approval. Recent Phase 1 data showed a 52.6% overall response rate in neuroendocrine carcinoma patients.

SOUTH SAN FRANCISCO - Ideaya Biosciences Inc. (NASDAQ:IDYA) announced plans to initiate registrational trials for IDE849, a DLL3-targeting antibody drug conjugate, in previously treated neuroendocrine carcinomas and extensive-stage small cell lung cancer by year-end, according to a press release statement.
The company plans to launch a single-arm extension cohort within its ongoing Phase 1/2 trial, enrolling approximately 90 previously treated gastroenteropancreatic neuroendocrine carcinoma patients. The cohort is designed to support a potential accelerated approval application, with overall response rate assessed by blinded independent central review as the primary endpoint.
Ideaya also intends to submit a protocol for a randomized Phase 3 trial of IDE849 in multiple neuroendocrine carcinoma subtypes, including gastroenteropancreatic neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The trial is intended to support conversion of potential accelerated approval to full approval, with progression-free survival as the primary endpoint for accelerated approval and overall survival for full approval.
The company plans to evaluate IDE849 at doses of 2.4 mg/kg and 3.5 mg/kg administered intravenously once every three weeks, based on data from its ongoing global Phase 1/2 trial.
In October, Ideaya’s partner Hengrui presented Phase 1 results at the European Society for Medical Oncology Congress showing an overall response rate of 52.6% among 19 neuroendocrine carcinoma patients, with median progression-free survival of 7.0 months and a nine-month overall survival rate of 82.4%.
The global Phase 1/2 trial showed a Grade 3 or higher treatment-related adverse event rate of 5% at the 2.4 mg/kg dose and 22.2% at the 3.5 mg/kg dose.
Ideaya licensed global development and commercialization rights to IDE849 outside Greater China from Hengrui in December 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Get a plan for IDYA before you enter. Swing trading IDYA means hours spent flipping through daily and weekly charts, then days second-guessing the plan once you're in. WarrenAI chart analysis gives you a trading plan for IDYA in under 60 seconds. It reads multiple timeframes, indicators, patterns, news and fundamental data, and hands you setups with entry, stop-loss and profit targets. Ask twice, get the same plan. Then it helps you stick to it. Set the suggested alerts and you'll know when IDYA hits your levels, without watching the screen all week. Now 55% off for a limited time.